Clinical Trials Logo

Clinical Trial Summary

This is a double blind, randomised, non-clinical study with 2 groups (1 investigational group and 1 comparator group) aiming to assess the effectiveness of PEA for reducing eczema severity compared to a base comparator moisturiser in healthy adults aged over 18 years.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05003453
Study type Interventional
Source RDC Clinical Pty Ltd
Contact
Status Completed
Phase Phase 2/Phase 3
Start date November 29, 2021
Completion date June 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT03568136 - Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis Phase 2
Recruiting NCT05575882 - Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream Intended for Very Dry, Irritated to Atopic Sensitive Skin. N/A
Recruiting NCT06436183 - A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis Phase 2
Recruiting NCT05642208 - Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis Phase 4
Active, not recruiting NCT05913791 - Nutrients-fortified Egg Consumption on Eczema Condition in Individuals With Eczema N/A
Completed NCT00560378 - Long-term Safety of Protopic in Atopic Eczema Phase 3
Terminated NCT00671528 - Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4) Phase 4
Terminated NCT05732454 - A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection Phase 2/Phase 3
Completed NCT03050151 - Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis Phase 1
Completed NCT03175354 - A Study in Subjects With Moderate Atopic Dermatitis Phase 2